| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb75b0b19820e3833ebdcb31603b242b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 |
| filingDate |
2015-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40291027c47872c598c068b427228766
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c75e78e93ed63783072adf03f0132522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7001260df1e892724aaab595677b4101
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24dd69b029f6ec44ae243bbc79122c70 |
| publicationDate |
2021-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2880388-T3 |
| titleOfInvention |
Rovatirelin dosage regimen for ataxia associated with spinocerebellar degeneration |
| abstract |
A pharmaceutical composition for use in the treatment of ataxia in spinocerebellar degeneration comprising, as active ingredient, a daily dose of 1.6 mg to 3.2 mg of rovatirelin or 1.6 mg to 3.2 mg of a pharmacologically acceptable dose of rovatirelin calculated as a free form, wherein the pharmaceutical composition is administered once daily. |
| priorityDate |
2015-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |